Evidence map›Paper›PMID 34586364›Full record

ArticleJAMA network open2021

Assessment of the Feasibility of Using Noninvasive Wearable Biometric Monitoring Sensors to Detect Influenza and the Common Cold Before Symptom Onset.

Emilia Grzesiak, Brinnae Bent, Micah T McClain, Christopher W Woods, Ephraim L Tsalik, Bradly P Nicholson, Timothy Veldman, Thomas W Burke, Zoe Gardener, Emma Bergstrom and 7 more

Registry-linked trialOpen access · goldAbstract readEvaluation Study
In one paragraph

Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06161454 (A Feasibility Study of Xofluza Treatment of Influenza in Pediatric Transplant Recipients, Waitlisted Subjects and Household Members After Early Infection Alerting Using Wearable Devices), which is not on this map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06161454 phase4completednot on this mapstarted 2023, after this paper: background citation

A Feasibility Study of Xofluza Treatment of Influenza in Pediatric Transplant Recipients, Waitlisted Subjects and Household Members After Early Infection Alerting Using Wearable Devices

TypeinterventionalSponsorChildren's Hospital of PhiladelphiaRan2023 to 2025Enrolled498ConditionsInfection, Coronavirus, Infections, Influenza, TransplantArmsBaloxavir Marboxil
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Emilia GrzesiakBiomedical Engineering Department, Duke University, Durham, North Carolina.
Brinnae BentBiomedical Engineering Department, Duke University, Durham, North Carolina.
Micah T McClainDuke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, North Carolina.
Christopher W WoodsDuke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, North Carolina.
Ephraim L TsalikDuke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, North Carolina.
Bradly P NicholsonDurham Veterans Affairs Medical Center, Durham, North Carolina.
Timothy VeldmanDepartment of Medicine, Duke Global Health Institute, Durham, North Carolina.
Thomas W BurkeDuke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, North Carolina.
Zoe GardenerDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Emma BergstromDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Ronald B TurnerDepartment of Pediatrics, University of Virginia School of Medicine, Charlottesville.
Christopher ChiuDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
P Murali DoraiswamyDepartment of Psychiatry, Duke University School of Medicine, Durham, North Carolina.
Alfred HeroDepartment of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor.
Ricardo HenaoDuke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, North Carolina.
Geoffrey S GinsburgDuke Center for Applied Genomics and Precision Medicine, Duke University Medical Center, Durham, North Carolina.
Jessilyn DunnBiomedical Engineering Department, Duke University, Durham, North Carolina.
Duke Medical Center · USDuke University · USImperial College London · GBDurham VA Medical Center · USDuke Institute for Health Innovation · USUniversity of Michigan–Ann Arbor · USUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Currently, there are no presymptomatic screening methods to identify individuals infected with a respiratory virus to prevent disease spread and to predict their trajectory for resource allocation. Objective: To evaluate the feasibility of using noninvasive, wrist-worn wearable biometric monitoring sensors to detect presymptomatic viral infection after exposure and predict infection severity in patients exposed to H1N1 influenza or human rhinovirus. Design, Setting, and Participants: The cohort H1N1 viral challenge study was conducted during 2018; data were collected from September 11, 2017, to May 4, 2018. The cohort rhinovirus challenge study was conducted during 2015; data were collected from September 14 to 21, 2015. A total of 39 adult participants were recruited for the H1N1 challenge study, and 24 adult participants were recruited for the rhinovirus challenge study. Exclusion criteria for both challenges included chronic respiratory illness and high levels of serum antibodies. Participants in the H1N1 challenge study were isolated in a clinic for a minimum of 8 days after inoculation. The rhinovirus challenge took place on a college campus, and participants were not isolated. Exposures: Participants in the H1N1 challenge study were inoculated via intranasal drops of diluted influenza A/California/03/09 (H1N1) virus with a mean count of 106 using the median tissue culture infectious dose (TCID50) assay. Participants in the rhinovirus challenge study were inoculated via intranasal drops of diluted human rhinovirus strain type 16 with a count of 100 using the TCID50 assay. Main Outcomes and Measures: The primary outcome measures included cross-validated performance metrics of random forest models to screen for presymptomatic infection and predict infection severity, including accuracy, precision, sensitivity, specificity, F1 score, and area under the receiver operating characteristic curve (AUC). Results: A total of 31 participants with H1N1 (24 men [77.4%]; mean [SD] age, 34.7 [12.3] years) and 18 participants with rhinovirus (11 men [61.1%]; mean [SD] age, 21.7 [3.1] years) were included in the analysis after data preprocessing. Separate H1N1 and rhinovirus detection models, using only data on wearble devices as input, were able to distinguish between infection and noninfection with accuracies of up to 92% for H1N1 (90% precision, 90% sensitivity, 93% specificity, and 90% F1 score, 0.85 [95% CI, 0.70-1.00] AUC) and 88% for rhinovirus (100% precision, 78% sensitivity, 100% specificity, 88% F1 score, and 0.96 [95% CI, 0.85-1.00] AUC). The infection severity prediction model was able to distinguish between mild and moderate infection 24 hours prior to symptom onset with an accuracy of 90% for H1N1 (88% precision, 88% sensitivity, 92% specificity, 88% F1 score, and 0.88 [95% CI, 0.72-1.00] AUC) and 89% for rhinovirus (100% precision, 75% sensitivity, 100% specificity, 86% F1 score, and 0.95 [95% CI, 0.79-1.00] AUC). Conclusions and Relevance: This cohort study suggests that the use of a noninvasive, wrist-worn wearable device to predict an individual's response to viral exposure prior to symptoms is feasible. Harnessing this technology would support early interventions to limit presymptomatic spread of viral respiratory infections, which is timely in the era of COVID-19.

Indexed as

Influenza A Virus, H1N1 SubtypeRhinovirusSeverity of Illness IndexWearable Electronic DevicesAdultArea Under CurveBiological AssayBiometryCohort StudiesCommon ColdEarly DiagnosisFeasibility StudiesFemaleHumansInfluenza, HumanMale

Identifiers

PMID34586364
PMCPMC8482058
OpenAlexW3204801709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.